rethinkPeptides Search
Menu
Home / Research library
Study breakdown

PYY3-36 From the Gut Suppresses Appetite by Changing Brain Hunger Gene Expression

RPEP-008042003Challis, B G; Pinnock, S B; Coll, A P; Carter, R N; Dickson, S L; O'Rahilly, S
Animal StudyPreliminary evidence
The takeaway

PYY3-36, a gut peptide released after eating, suppressed food intake in mice and altered hypothalamic neuropeptide expression, confirming it as a meal-derived satiety signal that changes brain hunger circuitry.

Gene reprogramming

PYY3-36 didn't just suppress appetite temporarily — it decreased brain hunger genes (NPY) and increased satiety genes (POMC)

What the researchers found

Peripheral PYY3-36 acutely suppressed food intake and altered hypothalamic neuropeptide expression (decreased NPY, increased POMC) in mice, confirming it as a gut-derived satiety signal that modulates central appetite gene programs.

Why it matters

Understanding how gut satiety peptides change brain hunger genes enables development of more effective appetite-suppressing drugs that work at the gene expression level.

How the study worked

Animal study. PYY3-36 administered peripherally to mice. Food intake measured. Hypothalamic neuropeptide gene expression (NPY, POMC, AgRP, CART) analyzed by in situ hybridization.

What this study cannot tell us

Mouse study with acute PYY3-36 administration. Chronic effects may differ. Whether the gene expression changes persist is unknown.

How to read the evidence

Preliminary animal evidence with both behavioral and molecular endpoints confirming gut-brain appetite signaling.

When this study was published

Published in 2003. PYY-based approaches are being explored alongside GLP-1 for obesity treatment.

The bigger picture

Modern obesity drugs (GLP-1 agonists) target one gut satiety signal. PYY3-36 represents another parallel pathway. Combining multiple gut peptide signals could produce superior appetite control.

Questions still open

  • Could PYY3-36 analogs be developed as obesity drugs?
  • Does combined GLP-1 + PYY therapy produce synergistic satiety?
  • Are PYY levels deficient in obese individuals?

Common questions

What is PYY and how does it affect appetite?
PYY3-36 is a gut hormone released after eating that tells your brain you're full. This study shows it not only suppresses appetite but actually changes the brain's hunger gene activity.
Could this help with weight loss?
PYY-based drugs are being studied for obesity. They represent a different appetite pathway from GLP-1 drugs (like Ozempic), and combining them could provide more powerful appetite control.

Read the original research

Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.

Biochemical and biophysical research communications, 311(4), 915-9

View on PubMed ↗

Citation

Challis, B G; Pinnock, S B; Coll, A P; Carter, R N; Dickson, S L; O'Rahilly, S. (2003). Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.. Biochemical and biophysical research communications, 311(4), 915-9.